Flora Growth (FLGC) vs. Its Competitors Head-To-Head Survey

Flora Growth (NASDAQ:FLGC) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Flora Growth to related businesses based on the strength of its risk, institutional ownership, dividends, profitability, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Flora Growth and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1	0	0	0	1.00
Flora Growth Competitors	4242	10457	18169	819	2.46

As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 22.72%. Given Flora Growth’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Flora Growth has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

36.0% of Flora Growth shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Flora Growth and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Flora Growth	$57.61 million	-$15.91 million	-0.09
Flora Growth Competitors	$1.88 billion	$138.21 million	11.13

Flora Growth’s rivals have higher revenue and earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Flora Growth’s rivals have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.

Profitability

This table compares Flora Growth and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Flora Growth Competitors	-278.38%	-150.31%	-21.96%

Summary

Flora Growth rivals beat Flora Growth on 11 of the 13 factors compared.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.